A Brief Review on Tumor Immunology

Abstract

The human immune system can eliminate unidentified proteins and contaminated tissues because it can discriminate between self and non-self proteins. The potential for cancer immunotherapy is largely predicated on the idea that cancer cells express particular antigens recognized by T-lymphocytes, as these cells have been demonstrated in animal models to cause tumor rejection. The primary determinants of immune checkpoint inhibitor response can be believed to be T cells' capacity to identify tumor surface antigen and their subsequent migration to the tumor. Neoangiogenesis, a crucial stage in carcinogenesis, is stimulated by tumor related macrophages. Tumors have a variety of strategies for avoiding the immune response. The hunt for therapeutic treatments can benefit from a thorough grasp of these mechanisms. A substantial corpus of clinical research demonstrates the growing importance of antibody-based cancer therapy. Further emerging as a promising development in cancer immunotherapy is adoptive cell treatment following lymphodepletion.